Please assess the completion status of the following clinical trial:

Trial Title: Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of androgen-independent prostate cancer~  * Osteoblastic metastases~ * No predominant visceral metastases~* Progressive disease after response to prior induction chemotherapy (prostate-specific antigen decline of at least 50% from baseline after 16 weeks of treatment)~* No symptomatic lymphadenopathy (i.e., scrotal or pedal edema)~PATIENT CHARACTERISTICS:~Age~* Any age~Performance status~* Not specified~Life expectancy~* Not specified~Hematopoietic~* Not specified~Hepatic~* Not specified~Renal~* Not specified~Other~* Adequate physiologic reserves~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* See Disease Characteristics~Endocrine therapy~* Not specified~Radiotherapy~* No prior radionuclide therapy~Surgery~* Not specified~Other~* No more than 3 prior cytotoxic treatments~* More than 6 months since prior celecoxib or rofecoxib

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I: Celecoxib (Type: EXPERIMENTAL): Doxorubicin IV over 30 minutes on days 1, 8, 15, and 22 + Strontium chloride Sr 89 IV on day 1, and oral celecoxib twice daily in absence of disease progression.
- Arm II: No Celecoxib (Type: EXPERIMENTAL): Doxorubicin IV over 30 minutes on days 1, 8, 15, and 22 + Strontium chloride Sr 89 IV on day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).